Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat(Eli Lilly (United States)), Alfonso de Dios(Eli Lilly (United States))

Cancer Research

December 9, 2024

10.1158/0008-5472.can-24-2608

Cited by 19

Related Papers

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

|Investigational New Drugs|2014|564

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

|Cell Reports|2020|108